Myoreval Clinical Experience


SIRT expression decreases significantly in older subjects contributing to increased acetylation of e-NOS

Increased prevalence of MI in patients with low SIRT & high MMP2

Increased hypertrophies in patients with low SIRTUINs

Myoreval treatment achieves significant increase in RCT, higher HDL levels, decreased TG & LDL, improved vascular tone, decreased prevalence of MI & decreased Hypertropies leading to a healthy heart and improved overall cardiac performance.

Sirtuins significantly alleviate arterial stiffness & improves vascular tone.

Myoreval treatment achieves significant increase in RCT, higher HDL levels, decreased TG & LDL, improved vascular tone, decreased prevalence of MI & decreased hypertropies leading to a healthy heart and improved overall cardiac performance.
  • No Serious Adverse Effect Reported.

    • Dosage used

    MYOREVAL Tablet - Once a Day , after meal. Can be started in patient with dyslipidemia with co-morbidites (e.g. diabetic dyslipidemia), and as a preventive therapy for reducing the risk of MI.

    MYOREVAL is to be added to the exsiting treatment regimes along with statins, nitrates etc.

    Duration of treatment

    Minumum 180 DAYS.

    >>>>>>>>>>>>>>